All Stories

  1. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

    Article • HIV Research & Clinical Practice, April 2019, Taylor & Francis

    Dr Jose L Casado, Marta Monsalvo Hernando, Pilar Vizcarra

  2. Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir

    Article • Infectious Diseases, February 2019, Taylor & Francis

    Dr Jose L Casado

  3. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection

    Article • Expert Review of Clinical Pharmacology, May 2018, Taylor & Francis

    Dr Jose L Casado

  4. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens

    Article • HIV Medicine, July 2015, Wiley

    Dr Jose L Casado

  5. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis

    Article • HIV Medicine, June 2015, Wiley

    Dr Jose L Casado

  6. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients

    Article • HIV Medicine, January 2015, Wiley

    Dr Alejandro Vallejo, Dr Jose L Casado

  7. Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio

    Article • PLoS ONE, January 2014, PLOS

    Dr Jose L Casado

  8. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

    Article • Journal of NeuroVirology, January 2014, Springer Science + Business Media

    Dr Jose L Casado

  9. Potencial papel de rilpivirina en el escenario de simplificación

    Article • Enfermedades Infecciosas y Microbiología Clínica, June 2013, Elsevier

    Dr Jose L Casado

  10. Social isolation in HIV-infected patients according to subjective patient assessment and DEXA-confirmed severity of lipodystrophy

    Article • AIDS Care, May 2013, Taylor & Francis

    Dr Jose L Casado

  11. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection

    Article • Journal of Viral Hepatitis, April 2013, Wiley

    Dr Jose L Casado

  12. Short Communication: Lamivudine Plus a Boosted-Protease Inhibitor as Simplification Strategy in HIV-Infected Patients: Proof of Concept

    Article • AIDS Research and Human Retroviruses, March 2013, Mary Ann Liebert Inc

    Dr Jose L Casado

  13. Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART

    Article • HIV Clinical Trials, February 2013, Taylor & Francis

    Dr Jose L Casado

  14. Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 Variants

    Article • HIV Clinical Trials, February 2013, Taylor & Francis

    Dr Jose L Casado

  15. Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, November 2012, Wolters Kluwer Health

    Dr Jose L Casado

  16. Missing Scheduled Visits in the Outpatient Clinic as a Marker of Short-Term Admissions and Death

    Article • HIV Clinical Trials, October 2012, Taylor & Francis

    Dr Jose L Casado

  17. The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients

    Article • Current HIV Research, August 2012, Bentham Science Publishers

    Dr Jose L Casado

  18. Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naïve HIV-Infected Patients: GESIDA-5808 Study

    Article • HIV Clinical Trials, June 2012, Taylor & Francis

    Dr Jose L Casado

  19. HIV Type 1 Viral Encephalitis After Development of Viral Resistance to Plasma Suppressive Antiretroviral Therapy

    Article • AIDS Research and Human Retroviruses, January 2012, Mary Ann Liebert Inc

    Dr Jose L Casado

  20. Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

    Article • PLoS ONE, December 2011, PLOS

    Dr Jose L Casado, Dr Alejandro Vallejo

  21. Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease

    Article • HIV Clinical Trials, October 2011, Taylor & Francis

    Dr Jose L Casado

  22. The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score

    Article • AIDS, April 2011, Wolters Kluwer Health

    Dr Jose L Casado

  23. Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study

    Article • Current HIV Research, October 2010, Bentham Science Publishers

    Dr Jose L Casado

  24. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

    Article • AIDS, May 2010, Wolters Kluwer Health

    Dr Jose L Casado

  25. Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, September 2008, Wolters Kluwer Health

    Dr Jose L Casado

  26. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation

    Article • AIDS, February 2008, Wolters Kluwer Health

    Dr Jose L Casado

  27. Validation of a Specific Questionnaire on Psychological and Social Repercussions of the Lipodystrophy Syndrome in HIV-infected Patients

    Article • Quality of Life Research, June 2006, Springer Science + Business Media

    Dr Jose L Casado

  28. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir

    Article • AIDS, April 2005, Wolters Kluwer Health

    Dr Jose L Casado

  29. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients

    Article • AIDS, November 2004, Wolters Kluwer Health

    Dr Jose L Casado

  30. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

    Article • AIDS, January 2004, Wolters Kluwer Health

    Dr Jose L Casado

  31. Differences in Durability of Treatment with Initial PI-Based Regimens

    Article • HIV Clinical Trials, December 2003, Taylor & Francis

    Dr Jose L Casado

  32. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1

    Article • AIDS, June 2003, Wolters Kluwer Health

    Dr Jose L Casado

  33. Overcoming Resistance: Virologic Response to a Salvage Regimen with the Combination of Ritonavir plus Indinavir

    Article • HIV Clinical Trials, February 2003, Taylor & Francis

    Dr Jose L Casado

  34. Individualizing salvage regimens

    Article • AIDS, January 2003, Wolters Kluwer Health

    Dr Jose L Casado

  35. Vascular disease in HIV-infected patients

    Article • AIDS, September 2002, Wolters Kluwer Health

    Dr Jose L Casado

  36. Extent and Importance of Cross-Resistance to Efavirenz after Nevirapine Failure

    Article • AIDS Research and Human Retroviruses, July 2002, Mary Ann Liebert Inc

    Dr Jose L Casado

  37. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

    Article • AIDS, March 2002, Wolters Kluwer Health

    Dr Jose L Casado

  38. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes

    Article • AIDS, May 2001, Wolters Kluwer Health

    Dr Jose L Casado

  39. A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

    Article • New England Journal of Medicine, January 2001, New England Journal of Medicine (NEJM/MMS)

    Dr Jose L Casado

  40. A Clinical Study of the Combination of 100 mg Ritonavir plus 800 mg Indinavir as Salvage Therapy: Influence of Increased Plasma Drug Levels in the Rate of Response

    Article • HIV Clinical Trials, July 2000, Taylor & Francis

    Dr Jose L Casado

  41. Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors

    Article • AIDS, March 2000, Wolters Kluwer Health

    Dr Jose L Casado

  42. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy

    Article • AIDS, August 1999, Wolters Kluwer Health

    Dr Jose L Casado

  43. Candidal Meningitis in HIV-infected Patients

    Article • AIDS Patient Care and STDs, September 1998, Mary Ann Liebert Inc

    Dr Jose L Casado

  44. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients

    Article • AIDS, July 1998, Wolters Kluwer Health

    Dr Jose L Casado

  45. Solitary Pulmonary Nodule Due to Leishmania in a Patient with AIDS

    Article • Clinical Infectious Diseases, February 1998, Oxford University Press (OUP)

    Dr Jose L Casado

  46. Salmonella Lung Involvement in Patients With HIV Infection

    Article • CHEST Journal, November 1997, Elsevier

    Dr Jose L Casado

  47. Candidal Meningitis in HIV‐Infected Patients: Analysis of 14 Cases

    Article • Clinical Infectious Diseases, September 1997, Oxford University Press (OUP)

    Dr Jose L Casado